Genta Incorporated to Present at U.S. Bancorp Piper Jaffray Health Care Conference
BERKELEY HEIGHTS, N.J., Jan. 23 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq:GNTA) today announced its participation at the U.S. Bancorp Piper Jaffray Health Care Conference in New York, NY. Raymond P. Warrell, Jr., M.D., Genta's Chairman and Chief Executive Officer, will provide an update on the Company's pipeline and registration trials on Tuesday, January 28, 2003 at 9:00 a.m. EST.
A live audio webcast of the presentation can be accessed through Genta's Investor Relations site at: genta.com A replay will be available for 90 days following the presentation.
About Genasense(TM)
Genasense (oblimersen sodium) works by inhibiting the production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced cell death. By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatments. Genasense is being developed in collaboration with Aventis and is currently in multiple, late-stage, randomized clinical trials in patients with malignant melanoma, multiple myeloma, chronic lymphocytic leukemia (CLL) and non-small cell lung cancer.
About Ganite(TM)
Ganite (gallium nitrate injection) has received regulatory approval in the U.S. and Canada as an intravenous treatment for patients with hypercalcemia who are unresponsive to hydration. Genta plans to market the drug by itself in the U.S., pending submission and approval by FDA of certain regulatory amendments to the existing NDA. Published reports have also suggested that the drug has direct antitumor activity. Genta has filed an Investigational New Drug (IND) exemption with the Oncology Division at FDA for the clinical evaluation of gallium nitrate, and the Company has an ongoing Phase 2b clinical trial in patients with non-Hodgkin's lymphoma. Genta currently plans to seek one or more additional registrations for the use of Ganite as an anticancer agent.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on anticancer therapy. The Company's research platform is anchored by oligonucleotide chemistry, particularly applications of antisense and decoy aptamer technology. Genasense(TM), the Company's lead compound, is being developed in collaboration with Aventis and is currently undergoing late-stage, Phase 3 clinical testing in several clinical indications. Genta's pipeline also comprises a portfolio of small molecules, including gallium-containing compounds and Androgenics compounds for prostate cancer, as well as an anticancer series of DNA-based compounds called "decoy aptamers." For more information about Genta, please visit our website at: genta.com
This press release and the webcast to follow contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report/Form 10-K for 2001.
SOURCE Genta Incorporated
CO: Genta Incorporated
ST: New Jersey
SU: TDS
prnewswire.com
01/23/2003 16:06 EST |
